Arrowhead Pharmaceuticals (ARWR) Net Cash Flow (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Net Cash Flow came in at -$14.1 million in Q1 2026, down 110.68% YoY from $132.2 million in Q1 2025, and up 43.53% on a QoQ basis from -$25.0 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Net Cash Flow (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Net Cash Flow data on file, last reported at -$14.1 million in Q1 2026.
- Quarterly Net Cash Flow fell 110.68% year-over-year to -$14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 96.99% YoY) and the FY2025 annual result came in at $124.3 million, up 1101.89% from the prior year.
- Net Cash Flow rose to -$14.1 million in Q1 2026, from -$25.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $132.2 million in Q1 2025 to a low of -$67.2 million in Q1 2023.
- A 5-year average of $5.4 million and a median of -$14.1 million in 2026 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow plunged 1197.61% — and 2024, when it surged 435.71%.
- Tracing ARWR's Net Cash Flow over 5 years: stood at $94.4 million in 2022, then slumped by 155.88% to -$52.7 million in 2023, then grew by 7.6% to -$48.7 million in 2024, then soared by 48.67% to -$25.0 million in 2025, then jumped by 43.53% to -$14.1 million in 2026.
- The last three Net Cash Flow figures came in at -$14.1 million (Q1 2026), -$25.0 million (Q4 2025), and $96.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | -134.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -134.24 Mn |
| Jun 30, 2026 | -134.24 Mn |
| Mar 31, 2026 | -14.12 Mn |
| Mar 31, 2026 | -14.12 Mn |
| Dec 31, 2025 | -25.01 Mn |
| Dec 31, 2025 | -25.01 Mn |
| Sep 30, 2025 | 96.78 Mn |
| Sep 30, 2025 | 96.78 Mn |
| Jun 30, 2025 | -56.01 Mn |
| Jun 30, 2025 | -56.01 Mn |
| Mar 31, 2025 | 132.22 Mn |
| Mar 31, 2025 | 132.22 Mn |
| Dec 31, 2024 | -48.73 Mn |
| Dec 31, 2024 | -48.73 Mn |
| Sep 30, 2024 | 28.95 Mn |
| Sep 30, 2024 | 28.95 Mn |
| Jun 30, 2024 | -58.08 Mn |
| Jun 30, 2024 | -58.08 Mn |
| Mar 31, 2024 | 69.46 Mn |
| Mar 31, 2024 | 69.46 Mn |